In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

A stage 4 prostate cancer survivor shares his story of positivity and gratitude. After doing some yard landscaping, I began to have some rather severe back pain and muscle spasms. My first thought was ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Our pilot study provides important evidence that microplastic exposure may be a risk factor for prostate cancer,” lead study ...

A tumor is an abnormal mass of tissue that forms when cells grow and divide more than they should, or do not die when they should. Tumors may be benign ...